Systematic Reviews
Copyright ©The Author(s) 2022.
World J Clin Cases. Oct 6, 2022; 10(28): 10109-10119
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10109
Table 1 Concept table for building the search strategy
Key concepts
Concept 1
Concept 2
Concept 3
Concept 4
COVID-19
Vaccines
Myocardial infarction
Link
Free text termsVaccinationHeart attackRelation
ShotInterrelation
Jab
Dose
Booster
Controlled vocabulary terms (MeSH terms, Emtree terms)2019 novel coronavirusViral VaccinesAnterior wall myocardial infarctionAssociation
Immunization
2019-nCoV disease
2019-nCoV infectionInferior wall myocardial infarction
COVID-19 pandemic
Non-ST elevated myocardial infarction
COVID-19 virus disease
ST elevation myocardial infarction
COVID-19 virus infection
SARS-CoV-2 infection
Table 2 Analysis/summary of important findings in various studies
Ref.Study designNo. of cases reportedType of vaccine givenTime during symptoms and vaccinationDose of vaccine, 1st or 2ndType of MIPatient outcome, dead or alive
Jabagi et al[10]Cross sectional6510/11113 (58.6%) after first dose, 4843/11113 (43.6%) after second dose of vaccinePfizerNot given1st and 2nd bothNot givenNA
Li et al[11]Cohort studyAges 35-74 incidence = between 1/100 and 1/1000 ages 75 and above incidence = between 1/10 and 1/100 patientsNANot givenNANot givenNA
Aye et al[12]Cohort and systematic review29 in cohort, 35 in systematic reviewPfizer 30/35 (86%), Moderna 1/35 (3%), AstraZeneca 4/35 (11%), Janssen 0%Median of 1 d2nd STEMI 20/35 (57%) NSTEMI 15/35 (43%)1 dead, remaining were alive
Maadarani et al[13]Case report1AstraZeneca1.5 h1st STEMI and NSTEMIAlive
Fazlollahi et al[14]Systematic review32 Pfizer, 1 ModernaCase 1: 6 h, case 2: 1 h, case 3: 30 min1st Case 1: NSTEMI, case 2: STEMI, case 3: STEMICase 1: alive, case 2: alive, case 3: dead
Şancı et al[15]Case report1Pfizer15 min1stSTEMIAlive
Chatterjee et al[16]Case report1AstraZeneca2 d1stSTEMIAlive
Jeet Kaur et al[17]Cross sectionalPfizer: 44, AstraZeneca: 1, Moderna: 3 Pfizer, AstraZeneca, and ModernaNANANANA
Iqbal et al[18]Case report1Moderna90 min1stNSTEMIAlive
Cari et al[19]Cross sectionalPfizer: 0.00044%, AstraZeneca: 0.00168%, Janssen: 0.00217%Pfizer, AstraZeneca, JanssenNot givenNANADead Pfizer: 0.00013%, AstraZeneca: 0.0004%, Janssen: 0.00048%
Tajstra et al[20]Case report1Pfizer30 min1stSTEMIDead
Flower et al[21]Case report1AstraZeneca8 d1stSTEMIAlive
Chiang et al[22]Case report1AstraZeneca8 d1stNSTEMIAlive
Fialho et al[23]Case report1AstraZeneca20 min1stSTEMIAlive
Hsu et al[24]Case report1AstraZeneca9 d1stSTEMIDead
Showkathali et al[25]Cross sectional37 (42%)AstraZeneca was the most used vaccine-28 (76%), while 9 (24%) had Covaxin< 1 wk: 9 (24%), 1-4 wk: 19 (52%), and > 4 wk: 9 (24%)1st (65%), 2nd dose (35%) STEMI and NSTEMINA
Whiteley et al[26]Cross sectionalPost vaccination < 28 d 3814/13787 (27.66%). Post vaccination > 28 d 2050/7758 (26.42%) AstraZeneca and PfizerNA1stNADead, < 28 d 16192/43766 (37.00%), > 28 d 11738/19496 (60.21%)
Shiravi et al[5]Narrative reviewNot givenPfizer, AstraZeneca, and Sinovac vaccines15 min to 2 dNANANA
Barda et al[27]Cross sectional59/892785 = 0.006%PfizerNot givenNANANA
Barsha et al[6]Case report1Moderna12 h1stNSTEMIAlive
Boivin et al[28]Case report1Moderna 1 h1stSTEMIAlive
Hippisley-Cox et al[29]Cross sectionalAstraZeneca: 0-7 d 1983/22079 (8.98%), 8-21 d 4028/22079 (18.23%), 22-28 d 1889/22.79 (8.55%). Pfizer: 0-7 d 1578/15124 (10.43%), 8-21 d 3457/15124 (22.83%), 22-28 d 1510/15124 (10.00%)AstraZeneca and PfizerAstraZeneca: 0-7 d 1983, 8-21 d 4028, 22-28 d 1889, Pfizer: 0-7 d 1578, 8-21 d 3457, 22-28 d 15101stNot givenNot given
Edler et al[30]Case series1Pfizer2 d1stNot givenDead
Hana et al[7]Systematic review1644 cases totalAstraZeneca, Pfizer and ModernaNANANot givenNA
Ho et al[31]Systematic review10Pfizer, Moderna, AstraZeneca, SinovacNA1stSTEMI and NSTEMISome dead, some alive
Sung et al[32]Case series2Moderna Case 1 < 24 h, case 2 < 12 h1stCase 1 STEMI, case 2 Not givenAlive
Pottegård et al[33]Cross sectionalIncidence rate 1.04/1.21, no of cases 20AstraZenecaNot given1st Not givenNA
Agostino et al[34]Case report1AstraZeneca12 d1st Not givenDead
Bardenheier et al[35]Cross sectional1Pfizer2 d2nd Not givenNA